|
|
|
| Clinical Efficacy of Bifidobacterium Quadripartitum Active Tablets Combined with Antibiotics in Severe Pneumonia Children and their Impact on Gut Microbiota and Inflammatory Cytokine Levels |
| CHEN Yajun, XIE Junqi, YUN Liangliang |
| Xuchang Hospital, Xuchang Henan 461000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of Bifidobacterium quadruple active tablets combined with antibiotics in severe pneumonia (SP) children on gut microbiota,pulmonary ultrasound score(LUS) and inflammatory cytokine levels. 【Methods】A total of 102 children with SP admitted to our hospital from January 2021 to August 2023 were selected and randomly divided into the control group (conventional symptomatic treatment and antibiotic treatment) and the observation group (combined with Bifidobacterium quadruple viable tablets on the basis of the control group) using a random number table method, with 51 cases in each group. Two groups were compared in terms of clinical efficacy, pre-and post-treatment lung function indicators [forced expiratory volume in one second (FEV1), vital capacity (VC), LUS], gut microbiota [Escherichia coli, Bifidobacterium, Enterococcus, Lactobacillus], inflammatory factors [interleukin (IL-10), C-reactive protein (CRP), soluble intercellular adhesion molecule-1 (sICAM-1), tumor necrosis factor alpha (TNF-α)] levels. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, FEV1, and VC in both groups were higher than before treatment, LUS was lower than before treatment, the difference was statistical significance in two groups(P<0.05); The levels of Bifidobacterium and Lactobacillus in both groups were higher than before treatment, while the levels of Enterococcus and Escherichia coli were lower than before treatment. The difference between the observation group and the control group was statistically significant (P<0.05); The levels of IL-10 in both groups were higher than before treatment, while the levels of CRP, sICAM-1, and TNF-α were lower than before treatment. The difference between the observation group and the control group was statistically significant (P<0.05). 【Conclusion】The combination of Bifidobacterium quadruple active tablets and antibiotics has good clinical efficacy in treating SP children, inhibiting inflammatory reactions, and improving lung function in children.
|
|
Received: 28 August 2023
|
|
|
|
|
|
[1] 肖水平. 重症肺炎患儿血清hs-CRP、SAA、PCT水平变化及与病情进展的关系研究[J].现代诊断与治疗,2024,35(6):878-880.
[2] 戴漆,林丹彤,陈瑜. 儿童重症肺炎支原体肺炎的临床特征分析[J].华中科技大学学报(医学版),2024,53(3):356-361.
[3] 刘盼盼.联用双歧杆菌四联活菌片与单用蒙脱石散治疗小儿腹泻的疗效及安全性比较[J].沈阳药科大学学报,2021,38(12):1334-1338.
[4] 胡亚美,江载芳.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2002:678-690.
[5] 葛梦娜,施科,任美玲,等.抗生素对儿童重症肺炎肠道菌群失调及生长发育的影响[J].药学服务与研究,2021,21(4):251.
[6] 欧霖洪,林晟,陈燕美,等.动态肺部超声评分对小儿重症肺炎病情诊断及呼吸治疗的指导研究[J].中外医学研究,2022,20(33):68-72.
[7] 阳池娇,白珺,潘志伟,等.儿童重症腺病毒肺炎与重症肺炎支原体肺炎临床特征及预后比较[J].中国医学创新,2020,17(11):145-149.
[8] 邵思.人免疫丙种球蛋白联合抗生素治疗小儿重症肺炎的疗效及对免疫功能和炎症反应的影响[J].中国妇幼保健,2021,36(12):2794-2797.
[9] 陈善佳,王欣,尹迪,等.肺炎新生儿肠道菌群及其代谢产物的分析[J].东南大学学报(医学版),2020,39(3):287-292.
[10] 陈华玲,顾园,杨进红,等.双歧杆菌四联活菌片辅助甲钴胺、依帕司他治疗糖尿病性腹泻患者的疗效观察[J].临床和实验医学杂志,2022,21(5):484-487.
[11] 闫登峰,朱春雨,胡淼.血必净联合纤维支气管镜吸痰灌洗治疗重症肺炎的疗效及对血清炎性因子水平的影响[J].安徽医药,2020,24(4):759-762.
[12] 刘珍欣,曹秋敏.血清IL-10、sICAM-1水平与重症肺炎患者病情严重程度的相关性[J].河南医学研究,2021,30(26):4957-4960.
[13] 俞荣明.宣白承气汤治疗对重症肺炎患者CRP、TNF-α、IgG、IL-6及中医证候积分的影响[J].四川中医,2021,39(11):96-99.
[14] 石燕华,陈赫赫.小潮气量联合抗生素阶梯疗法治疗小儿重症肺炎的效果[J].中国妇幼保健,2021,36(6):1305-1308.
|
|
|
|
2024, Vol. 41 
